A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease

Journal of Negative Results in Biomedicine
Eskandarain ShafuddinPeter N Black

Abstract

Azithromycin prophylaxis has been shown to reduce COPD exacerbations but there is poor evidence for other antibiotics. We compared exacerbation rates in COPD patients with a history of frequent exacerbations (at least three moderate or severe COPD exacerbations in the past two years) during a 12-week treatment course and over a subsequent 48-week follow up period. 292 patients were randomised to one of three treatments for 12 weeks: roxithromycin 300 mg daily and doxycycline 100 mg daily (n = 101); roxithromycin 300 mg daily (n = 97); or matching placebos (n = 94). There were no differences in the annualised moderate and severe exacerbation rates after treatment with roxithromycin/doxycycline (2.83 (95 % CI 2.37-3.40)) or roxithromycin only (2.69 (2.26-3.21)) compared to placebo (2.5 (2.08-3.03)) (p = 0.352 and p = 0.5832 respectively). Furthermore, there were no differences in the annualised exacerbation rates during 12-week treatment with roxithromycin/doxycycline (1.64 (95 % CI 1.17-2.30)), roxithromycin only (1.75 (1.24-2.41)) or placebo (2.23 (1.68-3.03)) (p = 0.1709 and p = 0.2545 respectively). There were also no significant differences between groups for spirometry or quality of life scores over either the 12-week treat...Continue Reading

References

Jul 1, 1992·Antimicrobial Agents and Chemotherapy·M R HammerschlagP M Roblin
Jan 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M R HammerschlagJ Schachter
Dec 1, 1991·The American Review of Respiratory Disease·C D BeatyT R Martin
Dec 1, 1989·Controlled Clinical Trials·R JaeschkeG H Guyatt
Nov 1, 1996·Journal of Clinical Epidemiology·D A RedelmeierR S Goldstein
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·D P StrachanP Elwood
Sep 14, 2001·Chest·T SuzukiH Sasaki
Aug 1, 2002·Thorax·F BlasiUNKNOWN Chlamydia InterAction with COPD (CIAC) Study Group
Nov 28, 2002·Thorax·T A R SeemungalP A Lambert
Jan 22, 2003·The Cochrane Database of Systematic Reviews·T StaykovaP Poole
Oct 30, 2003·The Cochrane Database of Systematic Reviews·D J EvansM Greenstone
Aug 30, 2008·American Journal of Respiratory and Critical Care Medicine·Terence A R SeemungalJadwiga A Wedzicha
Nov 11, 2008·International Journal of Chronic Obstructive Pulmonary Disease·Fernando J MartinezRichard Albert
Sep 29, 2009·European Journal of Internal Medicine·Georgios S PapaetisDora Orphanidou
Dec 23, 2009·Pulmonary Pharmacology & Therapeutics·Francesco BlasiEnrico Guffanti
Aug 26, 2011·The New England Journal of Medicine·Richard K AlbertUNKNOWN COPD Clinical Research Network
May 18, 2012·The New England Journal of Medicine·Wayne A RayC Michael Stein

❮ Previous
Next ❯

Citations

May 28, 2019·The Cochrane Database of Systematic Reviews·Christopher Jd ThreapletonEmma H Baker
Jan 19, 2019·The Cochrane Database of Systematic Reviews·Malene Plejdrup HansenChris B Del Mar
Oct 31, 2018·The Cochrane Database of Systematic Reviews·Samantha C HerathPhillippa Poole
Jan 16, 2021·The Cochrane Database of Systematic Reviews·Sadia JanjuaSofia Dias

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy test

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.